HONG KONG – In the aftermath of last year's highly controversial case of a researcher announcing the birth of two gene-edited babies in China, the National Health Commission (NHC) released a set of draft regulations that increases scrutiny over the use of new high-risk biomedical technologies, such as gene editing, stem cell technology, cloning and assisted reproduction.
HONG KONG – Hangzhou-based Chinese oncology drugmaker Betta Pharmaceuticals Co. Ltd. said Chinese regulators have given a green light for the company to conduct clinical trials for its novel compound, BPI-17509. Developed in-house, the oral small molecule is designed to selectively target fibroblast growth factor receptor (FGFR) 1, 2 and 3 to treat intrahepatic cholangiocarcinoma, bladder cancer and lung squamous cell carcinoma, among other FGFR-relevant solid tumors.
HONG KONG – Hangzhou-based Chinese oncology drugmaker Betta Pharmaceuticals Co. Ltd. said Chinese regulators have given a green light for the company to conduct clinical trials for its novel compound, BPI-17509. Developed in-house, the oral small molecule is designed to selectively target fibroblast growth factor receptor (FGFR) 1, 2 and 3 to treat intrahepatic cholangiocarcinoma, bladder cancer and lung squamous cell carcinoma, among other FGFR-relevant solid tumors.
HONG KONG – In the aftermath of last year's highly controversial case of a researcher announcing the birth of two gene-edited babies in China, the National Health Commission (NHC) released a set of draft regulations that increases scrutiny over the use of new high-risk biomedical technologies, such as gene editing, stem cell technology, cloning and assisted reproduction.
HONG KONG – Chinese drug regulators have approved the first homegrown biosimilar, Shanghai Henlius Biotech Inc.'s HLX-01, a biosimilar referencing Roche Holding AG's Mabthera (rituximab), to treat non-Hodgkin lymphoma (NHL). It will be marketed as Hanlikang.
HONG KONG – Chinese drug regulators have approved the first homegrown biosimilar, Shanghai Henlius Biotech Inc.'s HLX-01, a biosimilar referencing Roche Holding AG's Mabthera (rituximab), to treat non-Hodgkin lymphoma (NHL). It will be marketed as Hanlikang.
